AptarGroup Crescita futura
Criteri Future verificati 1/6
AptarGroup prevede che gli utili e i ricavi cresceranno rispettivamente di 10.2% e 5.7% all'anno. Si prevede che l'EPS crescerà di 9.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.8% in 3 anni.
Informazioni chiave
10.2%
Tasso di crescita degli utili
9.59%
Tasso di crescita dell'EPS
| Packaging crescita degli utili | 23.9% |
| Tasso di crescita dei ricavi | 5.7% |
| Rendimento futuro del capitale proprio | 12.80% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 03 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Aug 16
ATR: Recent Buybacks Will Support Future Upside Over The Coming Years
Analysts have lifted their price target on AptarGroup from $144 to $155, reflecting updated assumptions for slightly higher revenue growth, a modestly adjusted discount rate, and a broadly similar future P/E and profit margin profile. What’s in the News for AptarGroup AptarGroup reported that from April 1, 2026 to June 30, 2026, it repurchased 403,344 shares for US$50 million, representing 0.63% of its shares under the current buyback program.
Aggiornamento narrativa • Aug 02
ATR: Share Repurchases And Refillable Packaging Will Support Attractive Future Returns
The analyst price target for AptarGroup has been adjusted from about $161.43 to about $165.29. Analysts point to updated assumptions around revenue growth, profit margins, and a slightly different forward P/E multiple as the key drivers of this change.Seeking Alpha • Jun 29
AptarGroup Has Fallen Enough (Rating Upgrade)
Summary AptarGroup is upgraded from 'sell' to 'hold' as valuation improves after a significant share price decline. ATR's Q1 revenue rose 10.8% to $982.9M, but most growth was driven by FX and acquisitions, not organic expansion. Cash flows and EBITDA improved despite margin compression and net profit declines, particularly due to Beauty segment strength. ATR trades at a premium to peers, justified by its niche positioning, but not enough for a 'buy' rating. Read the full article on Seeking AlphaArticolo di analisi • Jun 18
AptarGroup (ATR) Stock Could Be 25.5% Undervalued on Its Drug Delivery Growth Narrative
Why AptarGroup Stock Is Back On Investor Radars AptarGroup (ATR) has drawn interest after recent share price moves, with the stock gaining about 6% over the past month while still showing a decline over the past year. For investors tracking AptarGroup as a packaging and drug delivery supplier, those mixed return figures may prompt a closer look at how its current valuation lines up with recent business performance and market expectations. See our latest analysis for AptarGroup. With the share...
Aggiornamento narrativa • Jun 17
ATR: Healthcare Packaging And Refillable Beauty Will Drive Future Upside Potential
The analyst price target for AptarGroup has been adjusted slightly to $211.14 from $211.25. Analysts cite updated assumptions for revenue growth, profit margins and the future P/E multiple as the main drivers of the change.Aggiornamento narrativa • Jun 03
ATR: Healthcare Packaging And Refillable Beauty Will Support Future Upside Potential
Analysts have nudged their price target for AptarGroup higher by refining assumptions on revenue growth to 6.11%, profit margin to 9.78%, and a future P/E of 33.28x. This lifts their valuation outlook without changing the underlying fair value estimate of $211.25 per share.Aggiornamento narrativa • May 12
ATR: Refillable Beauty And Nasal Drug Delivery Will Support Upside Potential
AptarGroup's updated analyst price target has edged down by about $1.54 to reflect slightly higher discount rate assumptions, along with modest adjustments to projected revenue growth, profit margins, and future P/E expectations, according to analysts. What's in the News AptarGroup and Clarins rolled out a custom reloadable airless packaging solution for Clarins Total Eye Lift Eye Cream, using Aptar Beauty’s patented Gaïa technology to support lower material usage while maintaining formula protection and a premium look.Articolo di analisi • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...Aggiornamento narrativa • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.Aggiornamento narrativa • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).Aggiornamento narrativa • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.Aggiornamento narrativa • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.Aggiornamento narrativa • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.Aggiornamento narrativa • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.Aggiornamento narrativa • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).Aggiornamento narrativa • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).Aggiornamento narrativa • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.Articolo di analisi • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Aggiornamento narrativa • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.Aggiornamento narrativa • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).Aggiornamento narrativa • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).Aggiornamento narrativa • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.Articolo di analisi • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...Aggiornamento narrativa • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 4,471 | 439 | 454 | 829 | 3 |
| 12/31/2027 | 4,143 | 401 | 444 | 717 | 7 |
| 12/31/2026 | 3,982 | 342 | 349 | 507 | 8 |
| 6/30/2026 | 3,933 | 363 | 308 | 583 | N/A |
| 3/31/2026 | 3,873 | 387 | 324 | 606 | N/A |
| 12/31/2025 | 3,777 | 393 | 295 | 570 | N/A |
| 9/30/2025 | 3,663 | 419 | 306 | 565 | N/A |
| 6/30/2025 | 3,611 | 392 | 342 | 616 | N/A |
| 3/31/2025 | 3,555 | 370 | 356 | 634 | N/A |
| 12/31/2024 | 3,583 | 375 | 349 | 643 | N/A |
| 9/30/2024 | 3,573 | 336 | 378 | 685 | N/A |
| 6/30/2024 | 3,557 | 320 | 323 | 629 | N/A |
| 3/31/2024 | 3,543 | 313 | 254 | 569 | N/A |
| 12/31/2023 | 3,487 | 284 | 257 | 575 | N/A |
| 9/30/2023 | 3,445 | 281 | 209 | 528 | N/A |
| 6/30/2023 | 3,389 | 251 | 159 | 484 | N/A |
| 3/31/2023 | 3,337 | 232 | 164 | 485 | N/A |
| 12/31/2022 | 3,322 | 239 | 163 | 479 | N/A |
| 9/30/2022 | 3,340 | 238 | 88 | 410 | N/A |
| 6/30/2022 | 3,329 | 231 | 46 | 365 | N/A |
| 3/31/2022 | 3,295 | 223 | 66 | 383 | N/A |
| 12/31/2021 | 3,227 | 244 | 56 | 363 | N/A |
| 9/30/2021 | 3,163 | 240 | 156 | 448 | N/A |
| 6/30/2021 | 3,096 | 256 | 256 | 518 | N/A |
| 3/31/2021 | 2,985 | 243 | 307 | 557 | N/A |
| 12/31/2020 | 2,929 | 214 | 318 | 570 | N/A |
| 9/30/2020 | 2,851 | 209 | 283 | 516 | N/A |
| 6/30/2020 | 2,793 | 202 | 273 | 521 | N/A |
| 3/31/2020 | 2,837 | 234 | N/A | 522 | N/A |
| 12/31/2019 | 2,860 | 242 | N/A | 514 | N/A |
| 9/30/2019 | 2,873 | 234 | N/A | 484 | N/A |
| 6/30/2019 | 2,838 | 217 | N/A | 380 | N/A |
| 3/31/2019 | 2,806 | 198 | N/A | 340 | N/A |
| 12/31/2018 | 2,765 | 195 | N/A | 314 | N/A |
| 9/30/2018 | 2,706 | 204 | N/A | 269 | N/A |
| 6/30/2018 | 2,664 | 218 | N/A | 330 | N/A |
| 3/31/2018 | 2,571 | 228 | N/A | 338 | N/A |
| 12/31/2017 | 2,469 | 220 | N/A | 325 | N/A |
| 9/30/2017 | 2,382 | 220 | N/A | 388 | N/A |
| 6/30/2017 | 2,348 | 220 | N/A | 390 | N/A |
| 3/31/2017 | 2,350 | 214 | N/A | 352 | N/A |
| 12/31/2016 | 2,331 | 206 | N/A | 325 | N/A |
| 9/30/2016 | 2,339 | 199 | N/A | 296 | N/A |
| 6/30/2016 | 2,335 | 200 | N/A | 269 | N/A |
| 3/31/2016 | 2,310 | 198 | N/A | 297 | N/A |
| 12/31/2015 | 2,317 | 199 | N/A | 324 | N/A |
| 9/30/2015 | 2,370 | 198 | N/A | 346 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di ATR ( 10.2% all'anno) è superiore al tasso di risparmio ( 3.7% ).
Guadagni vs Mercato: Si prevede che gli utili di ATR ( 10.2% all'anno) cresceranno più lentamente rispetto al mercato US ( 17.4% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di ATR cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di ATR ( 5.7% all'anno) crescerà più lentamente rispetto al mercato US ( 13.6% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di ATR ( 5.7% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di ATR sarà basso tra 3 anni ( 12.8 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/21 13:40 |
| Prezzo dell'azione a fine giornata | 2026/09/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
AptarGroup, Inc. è coperta da 16 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |